超分割再程放疗联合PD-1抑制剂治疗预后不良的复发性头颈部鳞癌:REPORT试验
REPORT试验为I/II期研究,评估纳武利尤单抗联合超分割再程放疗治疗不可手术的复发性或第二原发头颈部鳞癌。纳武利尤单抗双周给药,剂量递增至3.0 mg/kg未出现剂量限制性毒性。客观缓解率40%,中位缓解持续时间8个月,12个月无进展生存率15%,中位无进展生存6个月,中位总生存11个月。
要点
- 超分割再程放疗联合PD-1抑制剂在复发性头颈部鳞癌中可行且安全。
- 纳武利尤单抗双周3.0 mg/kg联合再程放疗未出现剂量限制性毒性。
- 客观缓解率40%,中位缓解持续时间8个月,中位总生存11个月。
核心结论
- 超分割再程放疗联合PD-1抑制剂治疗复发性头颈部鳞癌可行且安全。
研究设计与样本
- 再程放疗目标剂量60 Gy/40次、每周10次,纳武利尤单抗双周给药从放疗前2周开始、最长12个月或至进展。
- 主要终点为安全性和确定联合再程放疗的耐受性纳武利尤单抗剂量。
主要发现
- 全部患者PD-L1联合阳性评分>1。
- 纳武利尤单抗剂量递增至3.0 mg/kg双周给药未出现剂量限制性毒性。
- 客观缓解(完全和部分)率40%,平均缓解持续时间8个月;12个月无进展生存率15%,中位无进展生存6个月,中位总生存11个月。
临床怎么用
- 对于不可手术的复发性头颈部鳞癌,可考虑超分割再程放疗联合PD-1抑制剂。
- 联合方案中纳武利尤单抗双周3.0 mg/kg未出现剂量限制性毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent head and neck squamous cell carcinomas (HNSCC) in previously irradiated areas are a clinical challenge. Although palliative systemic treatment is a treatment option, the prognosis for many patients remains poor. Reirradiation offers benefit to some patients, but novel approaches are needed to improve durable responses. METHODS: This phase I/II trial evaluated the PD-1 inhibitor nivolumab combined with hyperfractionated reirradiation in patients with recurrent and/or second primary HNSCC ineligible for surgery. Reirradiation target dose was 60 Gy in 40 fractions, 10 fractions per week. Nivolumab was administered biweekly, starting two weeks prior to radiotherapy, for up to 12 months or until progression. Primary objectives were safety and determination of a tolerable nivolumab dose combined with reirradiation. RESULTS: Twenty patients (55 % male; median age of 72) were enrolled, most with recurrent oral cavity carcinoma. Thirteen participants (65 %) received a reirradiation dose of 60 Gy. All had a PD-L1 combined positive score > 1. Nivolumab dose-escalation reached 3.0 mg/kg biweekly without dose-limiting toxicity. Objective responses (complete and partial) occurred in 40 %, with a mean duration of 8 months. At 12 months the progression free survival (PFS) was 15 %. Median PFS was 6 months and medial overall survival 11 was months. CONCLUSION: Combining hyperfractionated reirradiation with a PD-1 inhibitor appears feasible and safe for recurrent HNSCC.
引用
- Eide HA, Grut H, Jebsen P, et al. Hyperfractionated reirradiation and PD-1 blockade in recurrent squamous cell head and neck carcinomas with poor prognosis, results from the REPORT-trial. Radiother Oncol. 2026. PMID: 41916446. doi:10.1016/j.radonc.2026.111514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。